OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Drug Safety is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada	48
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)	47
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study	29
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community	28
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana	19
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend	19
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions	17
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study	16
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study	16
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging	15
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database	15
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis	14
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey	13
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study	13
Corrigendum	13
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences	12
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review	11
Increasing patient involvement through self-administration of medication	10
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience	10
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study	9
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey	9
Impact of risk communication on patient’s safety during the pandemic	8
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic	8
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction	7
Artificial intelligence in drug development: reshaping the therapeutic landscape	7

The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology	7
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States	7
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database	6
Flow rate accuracy of infusion devices within healthcare settings: a systematic review	6
A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts	6
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system	6
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations	6
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward	6
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization	5
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries	5
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database	5
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers	5
Is there a risk of esketamine misuse in clinical practice?	5
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System	5
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries	5
Drug safety of frequently used drugs and substances for self-medication in COVID-19	5